Al-Madhagi Wafa M, Alshargabi Arwa, Alzomor Abdulkarim K Y, Sharhan Olla
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Sana'a University, Sana'a, Yemen.
Department of Pharmacy, Faculty of Medicine and Health Sciences, Al Nasser University, Sana'a, Yemen.
Adv Pharmacol Pharm Sci. 2023 Jul 29;2023:5512379. doi: 10.1155/2023/5512379. eCollection 2023.
Nausea and vomiting are symptoms associated with a lot of diseases and oral tablets may be unprofitable for patients especially those suffering from nausea and vomiting. Therefore, this study aimed to formulate a new meclizine and pyridoxine combination formula for chewable tablets and provide rapid drug absorption and decrease motion sickness. The new chewable formulation has been prepared to provide fast action, is more acceptable, and could be used for all age categories. Seven trials haves been carried out to prepare to find the suitable one where formula 7 of the chewable gum preparation exhibited good taste and hardness, while the gelatin formulation give an accepted formula after four trials with better taste and good acceptance. The prepared formulations give a dissolution profile of meclizine (95.53-102.8%) and pyridoxine (99.25 ± 115%) and assay (98 + 0.05-99.3 ± 0.8%) for meclizine and (97 ± 0.9-100.0 ± 0.08%) for the pyridoxine in three prepared formulations of chewable tablets. Followed by the evaluation, the formulation and testing them on human volunteers are carried out to confirm their effect to ensure acceptance and fast actions. The finding is promising for preparing a new route of administration of meclizine and pyridoxine combination to be used in the market.
恶心和呕吐是许多疾病相关的症状,口服片剂对患者可能无效,尤其是对那些患有恶心和呕吐的患者。因此,本研究旨在开发一种新的氯苯甲嗪和吡哆醇组合的咀嚼片配方,以实现药物的快速吸收并减轻晕动病。新的咀嚼片配方已制备完成,具有起效快、更易接受的特点,可用于所有年龄段。为找到合适的配方进行了七次试验,其中咀嚼胶制剂的配方7表现出良好的口感和硬度,而明胶制剂在四次试验后得到了一个可接受的配方,口感更好且接受度高。制备的制剂在三种咀嚼片配方中,氯苯甲嗪的溶出度为95.53 - 102.8%,吡哆醇的溶出度为99.25±115%,氯苯甲嗪的含量测定为98 + 0.05 - 99.3±0.8%,吡哆醇的含量测定为97±0.9 - 100.0±0.08%。在评估之后,对制剂进行配方调整并在人类志愿者身上进行测试,以确认其效果,确保其接受度和快速起效。该研究结果为开发一种新的氯苯甲嗪和吡哆醇组合的给药途径推向市场带来了希望。